{"id":"NCT03286842","sponsor":"AstraZeneca","briefTitle":"To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.","officialTitle":"A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-17","primaryCompletion":"2021-10-08","completion":"2021-10-08","firstPosted":"2017-09-19","resultsPosted":"2023-01-17","lastUpdate":"2023-01-17"},"enrollment":256,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HER2-ve Metastatic Breast Cancer","Germline BRCA1/2 Mutations","Somatic BRCA1/2 Mutations"],"interventions":[{"type":"DRUG","name":"Olaparib","otherNames":[]}],"arms":[{"label":"Olaparib","type":"EXPERIMENTAL"}],"summary":"This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve metastatic breast cancer associated with germline or somatic breast cancer susceptibility gene (gBRCA1/2 or sBRCA1/2) mutations.","primaryOutcome":{"measure":"Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants","timeFrame":"At every visit until the earliest of disease progression, death or end of study (up to 3 years)","effectByArm":[{"arm":"Olaparib gBRCAm Cohort","deltaMin":8.18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":123,"countries":["United States","Bulgaria","Canada","France","Germany","Hungary","Italy","Japan","Poland","Russia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["38112922","34087573"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00018&amp;attachmentIdentifier=aef63c74-06df-40d3-abe9-b750920e9fa5&amp;fileName=D0816C00018_CSP_30Nov2020_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00018&amp;attachmentIdentifier=c5f3b35e-e777-40b3-9b87-c363966f11d8&amp;fileName=D0816C00018_SAP_30Nov2020_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00018&amp;attachmentIdentifier=bf42d8ab-9b06-40de-a996-38cd1a8317d8&amp;fileName=D0816C00018_Redacted_CSRSynopsis.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":252},"commonTop":["Nausea","Anaemia","Asthenia","Vomiting","Fatigue"]}}